Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

Inclusion Criteria: * Adults 18 years of age at the time of screening or \>= 40 years and presenting at least one comorbidity : high blood pressure; a known obesity and/ or a known and treated diabete. * SARS-CoV-2 infection confirmed by molecular biology (RT-PCR on a nasopharyngeal or oropharyngeal swab) or by antigen test validated in the country according to national guidelines * A viral syndrome with or without uncomplicated pneumonia, defined as blood oxygen saturation level (SpO2) \>=94%. * Mild Covid-19 symptoms with an onset \< 7 days before inclusion. * Signed written consent from the patient or his/her representative. * No need an oxygen therapy according to international guidelines (WHO Progression Scale, grade 2 to 4) * Accepting and having the ability to be reached by telephone throughout the study. * Having designated a contact person who can be contacted in case of emergency. * Accepted to be reached by phone along throughout the study Exclusion Criteria: * Blood oxygen saturation level (SpO2) \< 94%. * Known hypersensitivity to investigational products * Chronic treatment with inhaled corticosteroids (up to 30 days) * Known history of renal or hepatic failure * Abnormal physical examination findings: * respiratory rate \< 25 per minute; * Clinical hypotension with associated signs justifying hospital care * Feeling unwell for more than 7 days prior to screening. * End-organ compromise requiring admission to a resuscitation or continuous care unit or short-term life-threatening comorbidity with life expectancy \< 3 months. * For any new antiviral included in the study, prior treatment with the antiviral, presence of contraindication to its use or intake of concomitant medication proscribed with its use. * Patients with known suicidal thoughts, severe psychiatric disorders or major depression that is uncontrolled or controlled by one of the prohibited drugs * Known history of long QT syndrome or severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with recovered ventricular fibrillation) * Unwilling or unable to comply with the requirements of the study protocol at any time during the study, e.g. no access to or not comfortable with use of a smartphone or with answering questions using a telephone, in the opinion of the Investigator or cannot use an inhalation chamber. * Any other reason that makes it impossible to monitor the patient during the study. * Enrolled in other clinical trials with unregistered drugs or with registered drugs that may interact with any of the study IPs or are contraindicated as concomitant therapy within the last 3 months prior to screening